CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade AstraZeneca PLC - GBP - AZNl CFD

117.28
0.43%
0.32
Low: 115.38
High: 117.3
Market Trading Hours* (UTC) Opens on Monday at 07:00

Mon - Fri: 07:00 - 11:00 11:03 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.32
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.023178 %
Charges from borrowed part ($-0.93)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.023178%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.00126 %
Charges from borrowed part ($0.05)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.00126%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency GBP
Margin 20%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

*Information provided by Capital.com

AstraZeneca PLC ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats
Prev. Close* 116.78
Open* 115.68
1-Year Change* 11.07%
Day's Range* 115.38 - 117.3
52 wk Range 93.99-128.29
Average Volume (10 days) 1.40M
Average Volume (3 months) 32.52M
Market Cap 183.20B
P/E Ratio 48.79
Shares Outstanding 1.55B
Revenue 35.22B
EPS 2.42
Dividend (Yield %) 2.03609
Beta 0.26
Next Earnings Date Jul 28, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 2, 2023 117.28 1.62 1.40% 115.66 117.40 115.30
May 31, 2023 116.78 2.22 1.94% 114.56 117.54 114.30
May 30, 2023 113.22 -4.28 -3.64% 117.50 118.28 113.22
May 26, 2023 116.62 -0.10 -0.09% 116.72 118.18 116.10
May 25, 2023 116.08 -0.70 -0.60% 116.78 118.08 115.64
May 24, 2023 116.34 -2.04 -1.72% 118.38 119.14 116.34
May 23, 2023 119.79 0.42 0.35% 119.37 121.71 118.86
May 22, 2023 119.77 0.22 0.18% 119.55 120.95 119.55
May 19, 2023 120.21 0.62 0.52% 119.59 120.61 119.22
May 18, 2023 119.60 0.11 0.09% 119.49 120.83 119.49
May 17, 2023 118.62 -2.43 -2.01% 121.05 121.69 118.50
May 16, 2023 120.31 1.10 0.92% 119.21 120.89 119.21
May 15, 2023 119.80 -0.21 -0.17% 120.01 120.49 119.58
May 12, 2023 119.72 0.56 0.47% 119.16 120.75 119.06
May 11, 2023 119.12 0.44 0.37% 118.68 119.87 118.52
May 10, 2023 117.98 0.00 0.00% 117.98 118.64 116.92
May 9, 2023 118.74 1.22 1.04% 117.52 119.28 117.52
May 5, 2023 118.92 0.90 0.76% 118.02 118.94 116.98
May 4, 2023 118.34 0.02 0.02% 118.32 118.66 117.42
May 3, 2023 118.68 0.24 0.20% 118.44 118.92 117.66

AstraZeneca PLC - GBP Events

Time (UTC) Country Event
Monday, June 5, 2023

Time (UTC)

23:00

Country

GB

Event

AstraZeneca PLC at ASCO Investor Meeting (Virtual)
AstraZeneca PLC at ASCO Investor Meeting (Virtual)

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 44351 37417 26617 24384 22090
Revenue 44351 37417 26617 24384 22090
Cost of Revenue, Total 8649 9542 5270 4824 4246
Gross Profit 35702 27875 21347 19560 17844
Total Operating Expense 40594 36361 21455 21460 18703
Selling/General/Admin. Expenses, Total 13512 11519 9338 8964 8479
Research & Development 9612 8519 6094 5320 5266
Depreciation / Amortization 4094 3044 1897 1812 1945
Unusual Expense (Income) 4820 3846 -763 863 -953
Other Operating Expenses, Total -93 -109 -381 -323 -280
Operating Income 3757 1056 5162 2924 3387
Interest Income (Expense), Net Non-Operating -815 -819 -716 -766 -775
Other, Net -441 -502 -530 -610 -619
Net Income Before Taxes 2501 -265 3916 1548 1993
Net Income After Taxes 3293 115 3144 1227 2050
Minority Interest -5 -3 52 108 105
Net Income Before Extra. Items 3288 112 3196 1335 2155
Net Income 3288 112 3196 1335 2155
Income Available to Common Excl. Extra. Items 3288 112 3196 1335 2155
Income Available to Common Incl. Extra. Items 3288 112 3196 1335 2155
Dilution Adjustment 0 0
Diluted Net Income 3288 112 3196 1335 2155
Diluted Weighted Average Shares 1560 1427 1313 1301 1267
Diluted EPS Excluding Extraordinary Items 2.10769 0.07849 2.43412 1.02613 1.70087
Dividends per Share - Common Stock Primary Issue 2.89361 2.84245 2.83031 2.89446 2.74532
Diluted Normalized EPS 3.8859 2.22705 1.88804 1.48501 0.85399
Interest Expense (Income) - Net Operating 0 0
Total Extraordinary Items
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 10879 11207 10982 10771 11390
Revenue 10879 11207 10982 10771 11390
Cost of Revenue, Total 2053 2417 2118 1904 2279
Gross Profit 8826 8790 8864 8867 9111
Total Operating Expense 8330 10113 9737 10232 10512
Selling/General/Admin. Expenses, Total 3196 3469 3353 3633 3057
Research & Development 2299 2638 2357 2431 2186
Depreciation / Amortization 954 1034 979 983 1098
Unusual Expense (Income) 230 331 1002 1298 1953
Other Operating Expenses, Total -402 224 -72 -17 -61
Operating Income 2549 1094 1245 539 878
Interest Income (Expense), Net Non-Operating -287 -316 -323 -292 -325
Net Income Before Taxes 2262 778 922 247 553
Net Income After Taxes 1804 902 1642 360 388
Minority Interest -1 -1 -2 0 -2
Net Income Before Extra. Items 1803 901 1640 360 386
Net Income 1803 901 1640 360 386
Income Available to Common Excl. Extra. Items 1803 901 1640 360 386
Income Available to Common Incl. Extra. Items 1803 901 1640 360 386
Dilution Adjustment
Diluted Net Income 1803 901 1640 360 386
Diluted Weighted Average Shares 1560 1560 1559 1560 1561
Diluted EPS Excluding Extraordinary Items 1.15577 0.57756 1.05196 0.23077 0.24728
Dividends per Share - Common Stock Primary Issue 0 1.9694 0 0.93017 0
Diluted Normalized EPS 1.27335 0.70833 0.99743 0.80833 1.24792
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 22593 26244 19544 15563 15591
Cash and Short Term Investments 6405 6398 7992 6218 5680
Cash 1411 1461 1182 755 893
Cash & Equivalents 4755 4868 6650 4614 3938
Short Term Investments 239 69 160 849 849
Total Receivables, Net 9923 8795 5651 5181 4345
Accounts Receivable - Trade, Net 7508 6324 3956 3813 2995
Total Inventory 4699 8983 4024 3193 2890
Prepaid Expenses 1329 1512 1735 865 1436
Other Current Assets, Total 237 556 142 106 1240
Total Assets 96483 105363 66729 61377 60651
Property/Plant/Equipment, Total - Net 9449 10171 8917 8335 7421
Property/Plant/Equipment, Total - Gross 17192 18495 17110 15852 14639
Accumulated Depreciation, Total -7743 -8324 -8193 -7517 -7218
Goodwill, Net 19820 19997 11845 11668 11707
Intangibles, Net 39307 42387 20947 20833 21959
Long Term Investments 1142 1237 1147 1459 922
Note Receivable - Long Term 592 504 325 348 515
Other Long Term Assets, Total 3580 4823 4004 3171 2536
Total Current Liabilities 26293 22594 20307 18117 16292
Accounts Payable 2550 2824 2350 1774 1720
Accrued Expenses 8303 8079 4994 5085 5148
Notes Payable/Short Term Debt 261 294 370 154 160
Current Port. of LT Debt/Capital Leases 5281 1599 2016 1856 1594
Other Current Liabilities, Total 9898 9798 10577 9248 7670
Total Liabilities 59446 66095 51107 48250 48183
Total Long Term Debt 23690 28888 17994 16217 17359
Long Term Debt 22965 28134 17505 15730 17359
Capital Lease Obligations 725 754 489 487 0
Deferred Income Tax 2944 6206 2918 2490 3286
Minority Interest 21 19 16 1469 1576
Other Liabilities, Total 6498 8388 9872 9957 9670
Total Equity 37037 39268 15622 13127 12468
Common Stock 387 387 328 328 317
Additional Paid-In Capital 35155 35126 7971 7941 4427
Retained Earnings (Accumulated Deficit) 1495 3755 7323 4858 7724
Total Liabilities & Shareholders’ Equity 96483 105363 66729 61377 60651
Total Common Shares Outstanding 1549.8 1549.4 1312.67 1312.14 1267.04
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 22266 22593 20224 20917 22647
Cash and Short Term Investments 6462 6405 4898 4887 5823
Cash & Equivalents 6232 6166 4458 4817 5762
Short Term Investments 230 239 440 70 61
Total Receivables, Net 10797 11252 10061 9612 9050
Accounts Receivable - Trade, Net 10289 10521 9336 8908 8683
Total Inventory 4967 4699 5078 6220 7624
Other Current Assets, Total 40 237 187 198 150
Total Assets 96687 96483 94185 96579 100273
Property/Plant/Equipment, Total - Net 9599 9449 9227 9627 10015
Goodwill, Net 20001 19820 19707 19821 19963
Intangibles, Net 39291 39307 39585 39900 41265
Long Term Investments 1234 1142 1102 1180 1237
Note Receivable - Long Term 682 835 792 881 864
Other Long Term Assets, Total 3614 3337 3548 4253 4282
Total Current Liabilities 24860 26293 24850 21815 22740
Payable/Accrued 19210 19040 17694 17821 17864
Notes Payable/Short Term Debt 568 261 584 636 724
Current Port. of LT Debt/Capital Leases 3289 5281 5034 1746 1570
Other Current Liabilities, Total 1793 1711 1538 1612 2582
Total Liabilities 60898 59446 59051 60647 63933
Total Long Term Debt 27646 23690 23681 27146 28805
Long Term Debt 26916 22965 23013 26461 28081
Capital Lease Obligations 730 725 668 685 724
Deferred Income Tax 2795 2944 3479 5275 5626
Minority Interest 22 21 20 19 19
Other Liabilities, Total 5575 6498 7021 6392 6743
Total Equity 35789 37037 35134 35932 36340
Common Stock 387 387 387 387 387
Additional Paid-In Capital 35159 35155 35137 35134 35131
Retained Earnings (Accumulated Deficit) 243 1495 -390 411 822
Total Liabilities & Shareholders’ Equity 96687 96483 94185 96579 100273
Total Common Shares Outstanding 1549.85 1549.8 1549.51 1549.48 1549.45
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 2501 -265 3916 1548 1993
Cash From Operating Activities 9808 5963 4799 2969 2618
Cash From Operating Activities 5480 6530 3149 3762 3753
Non-Cash Items 542 141 -332 -103 -1276
Cash Taxes Paid 1623 1743 1562 1118 537
Cash Interest Paid 849 721 733 774 676
Changes in Working Capital 1285 -443 -1934 -2238 -1852
Cash From Investing Activities -2960 -11058 -285 -657 963
Capital Expenditures -2571 -2200 -2606 -2460 -1371
Other Investing Cash Flow Items, Total -389 -8858 2321 1803 2334
Cash From Financing Activities -6823 3649 -2203 -1765 -2044
Financing Cash Flow Items -1047 -178 -101 4 -67
Total Cash Dividends Paid -4364 -3856 -3572 -3592 -3484
Issuance (Retirement) of Stock, Net 29 29 30 3525 34
Issuance (Retirement) of Debt, Net -1441 7654 1440 -1702 1473
Foreign Exchange Effects -80 -62 12 5 -38
Net Change in Cash -55 -1508 2323 552 1499
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 2262 2501 1723 800 553
Cash From Operating Activities 3133 9808 7410 4480 3232
Cash From Operating Activities 1502 5480 4000 2666 1309
Non-Cash Items -391 542 172 15 -12
Cash Taxes Paid 225 1623 1335 1006 228
Cash Interest Paid 257 849 608 386 194
Changes in Working Capital -240 1285 1515 999 1382
Cash From Investing Activities -1246 -2960 -2711 -968 -168
Capital Expenditures -1470 -2571 -2017 -906 -363
Other Investing Cash Flow Items, Total 224 -389 -694 -62 195
Cash From Financing Activities -2031 -6823 -6465 -5035 -3740
Financing Cash Flow Items -840 -1047 -1047 -997 -997
Total Cash Dividends Paid -3047 -4364 -4364 -2971 -2971
Issuance (Retirement) of Stock, Net 4 29 11 8 5
Issuance (Retirement) of Debt, Net 1852 -1441 -1065 -1075 223
Foreign Exchange Effects -11 -80 -86 -35 -9
Net Change in Cash -155 -55 -1852 -1558 -685
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.5098 100893184 1200 2023-01-31 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.1999 65092368 768 2023-01-31 LOW
Capital Research Global Investors Investment Advisor 4.1199 63852512 752 2023-01-31 LOW
Investor AB Private Equity 3.3299 51608948 608 2023-01-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.8464 44114976 -1215991 2022-12-14 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.2269 34514808 15209 2023-05-01 LOW
Capital World Investors Investment Advisor 1.7648 27351981 2675871 2022-12-14 LOW
BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 1.2141 18816198 280706 2023-05-01 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 1.1273 17471628 -78807 2023-05-01 LOW
GQG Partners, LLC Investment Advisor 1.0697 16579162 1036509 2022-12-14 MED
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.9835 15243057 -36818 2023-05-01 LOW
State Street Global Advisors (UK) Ltd. Investment Advisor/Hedge Fund 0.6302 9767199 -6522 2023-05-01 LOW
Nuveen LLC Pension Fund 0.6158 9543355 495683 2022-12-14 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5411 8386244 -95567 2022-12-14 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.4985 7725827 -10523 2023-05-01 LOW
Handelsbanken Kapitalförvaltning AB Investment Advisor/Hedge Fund 0.4931 7642032 181760 2023-04-30 LOW
Aviva Investors Global Services Limited Investment Advisor/Hedge Fund 0.4919 7623953 -442236 2023-05-01 LOW
M & G Investment Management Ltd. Investment Advisor 0.4722 7318503 -220395 2023-05-01 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.4707 7294740 0 2023-05-01 LOW
BlackRock Investment Management, LLC Investment Advisor/Hedge Fund 0.4379 6787247 -85660 2023-03-31 LOW

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

535K+

Traders

87K+

Active clients monthly

$113M+

Monthly investing volume

$64M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

AstraZeneca - GBP Company profile

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.

Industry: Pharmaceuticals (NEC)

1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

71.98 Price
+2.450% 1D Chg, %
Long position overnight fee -0.0201%
Short position overnight fee -0.0018%
Overnight fee time 21:00 (UTC)
Spread 0.04

Gold

1,948.36 Price
-1.480% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

14,557.80 Price
+0.640% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 3.0

XRP/USD

0.53 Price
-0.350% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00395

Still looking for a broker you can trust?

Join the 535.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading